COVID-19 Vaccine Effectiveness at a Referral Hospital in Northern Peru: A Retrospective Cohort Study
暂无分享,去创建一个
Mario J. Valladares-Garrido | C. Díaz-Vélez | V. Failoc-Rojas | C. Peralta | Sandra Zeña-Ñañez | J. B. Puicón-Suárez
[1] Heber Silva-Díaz,et al. Diversidad genómica en SARS-CoV-2: Mutaciones y variantes , 2021, Revista del Cuerpo Médico Hospital Nacional Almanzor Aguinaga Asenjo.
[2] Shigui Yang,et al. Impact of Coinfection With SARS-CoV-2 and Influenza on Disease Severity: A Systematic Review and Meta-Analysis , 2021, Frontiers in Public Health.
[3] R. Arbel,et al. BNT162b2 Vaccine Booster and Mortality Due to Covid-19 , 2021, The New England journal of medicine.
[4] M. Abu-Farha,et al. Robust Antibody Levels in Both Diabetic and Non-Diabetic Individuals After BNT162b2 mRNA COVID-19 Vaccination , 2021, Frontiers in Immunology.
[5] Michael I. Mandel,et al. Waning Immunity after the BNT162b2 Vaccine in Israel , 2021, The New England journal of medicine.
[6] M. Hernán,et al. Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study , 2021, The Lancet.
[7] P. Dormitzer,et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months , 2021, The New England journal of medicine.
[8] William F. Fadel,et al. Effectiveness of Covid-19 Vaccines in Ambulatory and Inpatient Care Settings , 2021, The New England journal of medicine.
[9] Yu Sun,et al. Effectiveness of the WHO-Authorized COVID-19 Vaccines: A Rapid Review of Global Reports till 30 June 2021 , 2021, medRxiv.
[10] Raju Vaishya,et al. Lack of vaccination and associated comorbidities predispose to the need for intensive care in individuals infected with the delta variant – A case cohort study from a tertiary care hospital in New Delhi, India , 2021, Diabetes & Metabolic Syndrome: Clinical Research & Reviews.
[11] Catalina Pírez,et al. Inmunizaciones como estrategia de salud pública , 2021 .
[12] A. Lenzi,et al. Central obesity, smoking habit, and hypertension are associated with lower antibody titres in response to COVID‐19 mRNA vaccine , 2021, Diabetes/metabolism research and reviews.
[13] I. Hung,et al. Single-dose Oxford–AstraZeneca COVID-19 vaccine followed by a 12-week booster , 2021, The Lancet.
[14] S. Vollmer,et al. The disproportionate excess mortality risk of COVID-19 in younger people with diabetes warrants vaccination prioritisation , 2021, Diabetologia.
[15] P. Dormitzer,et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine , 2020, The New England journal of medicine.
[16] Wenling Wang,et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial , 2020, The Lancet Infectious Diseases.
[17] S. Flasche,et al. Use of seasonal influenza and pneumococcal polysaccharide vaccines in older adults to reduce COVID-19 mortality , 2020, Vaccine.
[18] Jessica M Franklin,et al. Alternative approaches for confounding adjustment in observational studies using weighting based on the propensity score: a primer for practitioners , 2019, BMJ.
[19] E. Stuart,et al. Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies , 2015, Statistics in medicine.
[20] M. Fernández,et al. Impact of Obesity and Metabolic Syndrome on Immunity. , 2016, Advances in nutrition.